Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WASH complex subunit 3 (WASHC3)
- Target
- WASHC3
- Molecular classification
- Other (protein complex subunit, coiled-coil domain protein, nucleation-promoting factor), Not classified as a receptor, enzyme, transporter, or ion channel
01
Overview
WASH complex subunit 3 (WASHC3, also known as CCDC53) is a protein that acts as an integral member of the WASH complex, which is responsible for regulating actin polymerization at the surface of endosomes. The WASH complex promotes actin nucleation via the Arp2/3 complex, playing a key role in sorting and trafficking of transmembrane cargo proteins, including certain G protein-coupled receptors (GPCRs) such as PTH1R. WASHC3's function is essential for proper endosomal dynamics, growth plate chondrocyte differentiation, and cell signaling. Genetic variants in WASHC3 can lead to human disease phenotypes including impaired skeletal growth (short stature), distinctive facial features, and neurodevelopmental disorders. WASHC3 is not currently considered a direct therapeutic target by pharmacological compounds, but pathogenic variants may inform clinical diagnostics in rare genetic syndromes.
- Other names
- CCDC53Coiled-coil domain-containing protein 53AD-016CGI-116x0009 (rare/obsolete)2900091E11RIK (mouse)5730495F03Rik (mouse)RG1563761 (rat)
02
Mechanism of action
Not applicable; WASHC3 is not the direct target of any drugs
03
Biological functions
Actin filament polymerization: Promotes actin nucleation via the Arp2/3 complex at endosomal surfacesEndosomal transport and sorting: Regulates fission of endosomal tubules and endosomal trafficking of transmembrane proteins, especially those with PDZ-binding motifsExocytosisRegulation of receptor trafficking: Modulates endosomal sorting and signaling of receptors suchs as parathyroid hormone 1 receptor (PTH1R)
04
Disease associations
Skeletal dysplasia/short stature: Variants impair growth plate chondrocyte differentiation and longitudinal bone growthNeurodevelopmental abnormalities: Distinctive facial dysmorphism and variable neurodevelopmental phenotypes associated with WASHC3 mutationsRitscher-Schinzel Syndrome and Intellectual Developmental Disorder, Autosomal Recessive 43 (reported associations in gene databases)
05
Safety considerations
None directly applicable for drug targeting, as WASHC3 is not a therapeutic target. Safety issues may arise from gene defects leading to disease, such as growth abnormalities and neurodevelopmental syndromes
06
Biomarkers
None established specifically for patient selection or efficacy monitoring; mutations in WASHC3 may serve as genetic biomarkers in rare inherited disorders
Beyond the preview
Go deeper on WASH complex subunit 3 (WASHC3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WASH complex subunit 3 (WASHC3).